Objective:

To review the current clinical-stage therapies in development for geographic atrophy (GA) associated with age-related macular degeneration (AMD).

Key Findings:

• Pegcetacoplan and Avacincaptad pegol have shown modest reductions in lesion growth in clinical trials, with specific percentages noted.
• Vonaprument is currently being tested for its ability to prevent vision loss, with expected outcomes from the ongoing trials.
• Elamipretide has shown some functional improvements despite not meeting primary endpoints in trials, indicating potential for further research.
• Gene therapies like JNJ-81201887 and CTx001 are in various stages of clinical evaluation, with specific trial phases and goals outlined.

Interpretation:

The development of therapies for GA reflects a shift towards targeting specific disease mechanisms, particularly through complement inhibition and gene therapy, with the potential for more effective and durable treatments.

Limitations:

• Long-term safety and efficacy data for new therapies are still pending, which may affect clinical adoption.
• Some therapies have shown only modest efficacy in reducing lesion growth, raising questions about their overall impact on patient outcomes.

Conclusion:

The therapeutic landscape for GA is evolving with promising investigational therapies that may offer improved outcomes for patients suffering from this debilitating condition.